Eleanor Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Outpatient addiction and mental health treatment platform, Boston MA, raised $50M+. Value-based care model integrating SUD treatment with mental health support.
About
Eleanor Health is a Boston, Massachusetts-based behavioral health company founded in 2019 that provides value-based outpatient treatment for substance use disorder (SUD) combined with mental health care. The company has raised over $50 million and operates in multiple states through a hybrid model that combines telehealth with community-based care hubs staffed by multidisciplinary care teams. Eleanor Health treats addiction to opioids, alcohol, and other substances alongside co-occurring mental health conditions such as depression, anxiety, and PTSD.\n\nEleanor Health's care model is built around value-based contracts with Medicaid managed care organizations and commercial health plans, aligning the company's financial incentives with patient outcomes rather than visit volume. Care teams include addiction medicine specialists, therapists, care coordinators, and community health workers who support patients through recovery with a whole-person approach. The platform integrates medication-assisted treatment (MAT), individual and group therapy, and social needs navigation into a coordinated care program.\n\nThe company focuses on serving Medicaid populations with high rates of co-occurring substance use and mental health conditions, a population that historically experiences fragmented care across separate addiction and mental health service systems. Eleanor Health's integrated model is designed to reduce emergency department utilization, hospitalizations, and crisis episodes among high-need members. The company has partnered with several state Medicaid programs and commercial payers to expand access to its model across the Southeast and other regions.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.